Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine for Myocardial Injury in Diabetic Patients Undergoing PCI
NCT03715582Phase 3Unknown
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Oct 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Myocardial injury comparing Trimetazidine with Placebo (2 arms). Primary endpoints: Peak values of troponin after PCI at 24 hours and Peak values of CKMB after PCI at 24 hours. Status: unknown.
02
Drugs
trimetazidine
03
Conditions
Myocardial injury
Beyond the preview
Go deeper on NCT03715582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715582.